$HALO News

Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth Momentum

Halozyme to Report Third Quarter 2026 Financial and Operating Results

2 Reasons to Like HALO (and 1 Not So Much)

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

Here's How Much $100 Invested In Halozyme Therapeutics 5 Years Ago Would Be Worth Today

Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong Profitability

JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78

HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value?

Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?

Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock.

Halozyme stock rises after winning injunction against Merck

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

Halozyme Therapeutics (NASDAQ:HALO): High Growth Momentum Meets Breakout Setup

Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

Halozyme Announces Appointment of Jim Daly to its Board of Directors